2026-01-04 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co. (MRK) based on the provided data:

**1) Performance vs. S&P 500 (VOO)**

*   **Company Overview:** Merck & Co. is a global pharmaceutical company engaged in the research, development, manufacturing, and marketing of a wide range of healthcare products.
*   **Cumulative Return:** MRK (22.93%) significantly underperformed VOO (91.00%).
*   **Divergence:** The current divergence is -69.7, with a relative divergence of 22.5. This means MRK's underperformance is substantial and near the low end of its historical divergence range.

*   **Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap(B) |
|------------|---------|--------|---------|-------|--------|
| 2016-2018  | 24.0%   | 14.7%  | 21.0%   | 0.7   | 182.1  |
| 2017-2019  | 37.0%   | 14.7%  | 20.0%   | 0.7   | 216.8  |
| 2018-2020  | 13.0%   | 19.3%  | -8.0%   | 0.7   | 195.0  |
| 2019-2021  | 0.0%    | 19.3%  | -43.0%  | 0.6   | 191.4  |
| 2020-2022  | 14.0%   | 16.3%  | 16.0%   | 0.5   | 277.1  |
| 2021-2023  | 31.0%   | 14.3%  | 30.0%   | 0.3   | 272.3  |
| 2022-2024  | -5.0%   | 24.9%  | -24.0%  | 0.3   | 248.5  |
| 2023-2025  | -24.0%  | 39.0%  | -86.0%  | 0.3   | 262.9  |

*   **Analysis:**
    *   Beta: MRK's beta consistently decreased from 0.7 to 0.3 over the years, indicating a decline in its correlation with the market. This could imply that MRK is becoming less sensitive to overall market movements.
    *   Alpha: Alpha has been highly volatile. While there were periods of strong positive alpha (outperformance), recent years show negative alpha, indicating underperformance relative to the market, even adjusted for risk.
    *   CAGR & MDD: The table shows varying performance with some periods showing good growth (e.g., 2017-2019) but recent years have seen negative growth. The Max Drawdown also reflects some volatility, particularly in recent years.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 106.45
*   **Previous Close:** 105.26
*   **Change:** 1.13
*   **5-day SMA:** 106.234
*   **20-day SMA:** 102.0115
*   **60-day SMA:** 94.4825

*   **Analysis:**
    *   The current price is above the 5-day, 20-day, and 60-day moving averages, suggesting a short-term uptrend.
    *   The recent price increase (change of 1.13) is noticeable, and the current price is slightly higher than the 5-day SMA, indicating the uptrend is relatively recent.
    *   The price is significantly above the 60-day SMA, which suggests that the current price has had a recent recovery.

**3) Indicators**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 75.58 (Overbought)
*   **PPO:** 0.0841
*   **Hybrid Signal:** "cash_0%_Buy 90% of cash (8 shares - Safe - MRI:0.80) Monthly invest 0.8% of total investment ($1,000.00)" - Suggests a buying opportunity, but with caution due to the MRI.
*   **Recent (20 days) relative divergence change:** 1.5 (+) - Short-term increase.
*   **Expected Return (%):** -29.1 - Expected underperformance compared to S&P 500 over the long term.

*   **Analysis:**
    *   MRI suggests a medium level of risk, implying that while there are some risks, it might still be a reasonable investment.
    *   RSI being over 70 indicates that the stock is overbought, which could signal a potential pullback in the near future.
    *   A positive PPO suggests that the short-term moving average is above the long-term moving average, reinforcing the uptrend seen in the moving average analysis.
    *   The Hybrid Signal suggests a cautious buying strategy.
    *   The negative expected return is a significant concern, especially for long-term investors.

**4) Recent News & Significant Events**

*   **[2026-01-04]** Merck stock slips as U.S. markets closed. (ts2.tech)
*   **[2025-12-16]** Morgan Stanley lifts Merck's price target due to an improved biopharma outlook. (Yahoo Finance)
*   **[2026-01-03]** Financiere des Professionnels Fonds d investissement inc. Raises Stock Holdings. (MarketBeat)
*   **[2026-01-01]** Seeking Alpha article discusses Merck's low valuation and strategy post-Keytruda.
*   **[2025-12-16]** Quiver Quantitative reports that Merck's stock is down 3%.
*   **[2025-12-19]** Motley Fool compares Pfizer and Merck as 2026 buys.

*   **Analysis:**
    *   The Morgan Stanley price target lift and Financiere des Professionnels increasing holdings are positive signals.
    *   The Seeking Alpha article highlighting the low valuation could indicate a potential value play, but the "post-Keytruda playbook" suggests there are significant strategic changes underway that could introduce uncertainty.
    *   The report of a 3% drop in December indicates some recent negative price action.
    *   The Motley Fool comparison suggests the need to consider alternatives within the pharmaceutical sector.

4-2) Analyst Opinions

*   **Consensus:** Buy (~2.0)
*   **Target Price:** 110.04 (Average)

*   **Analysis:** Analysts generally have a positive outlook with a 'Buy' consensus and an average target price implying some upside potential from the current price. However, there are no recent rating changes given.

**5) Recent Earnings Analysis**

| 날짜       | EPS    | 매출        |
|------------|--------|-------------|
| 2025-11-05 | 2.32   | 17.28 B$    |
| 2025-08-05 | 1.76   | 15.81 B$    |
| 2025-05-02 | 2.01   | 15.53 B$    |
| 2024-11-06 | 1.25   | 16.66 B$    |
| 2025-11-05 | 1.25   | 16.66 B$    |

*   **Analysis:**
    *   EPS (Earnings Per Share) has been volatile but generally trending upwards in recent quarters compared to last year.
    *   Revenue shows consistent performance above $15 Billion in each quarter, suggesting stable demand for the company's products.

**6) Financial Information**

Revenue and Profitability:

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.28B    | 77.69%        |
| 2025-06-30   | $15.81B    | 77.50%        |
| 2025-03-31   | $15.53B    | 77.98%        |
| 2024-12-31   | $15.62B    | 75.50%        |
| 2024-09-30   | $16.66B    | 75.51%        |

Capital and Profitability:

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-09-30   | $51.85B    | 11.16%    |
| 2025-06-30   | $48.99B    | 9.04%     |
| 2025-03-31   | $48.34B    | 10.51%    |
| 2024-12-31   | $46.31B    | 8.08%     |
| 2024-09-30   | $44.50B    | 7.09%     |

*   **Analysis:**
    *   **Revenue:** Revenue has been consistent, with recent quarters showing a slight upward trend.
    *   **Profit Margin:**  Very high and stable profit margins, indicating strong pricing power and efficient operations.
    *   **Equity:** Growing equity base, which suggests the company is retaining earnings and/or raising capital effectively.
    *   **ROE (Return on Equity):** ROE has been trending upward, reflecting improving profitability relative to the company's equity.

**7) Comprehensive Analysis**

Merck (MRK) presents a mixed picture:

*   **Negatives:**
    *   Significant underperformance compared to the S&P 500, with a deeply negative divergence.
    *   Negative expected return over the long term.
    *   RSI indicates the stock is currently overbought, suggesting a potential pullback.
    *   "Post-Keytruda playbook" implies a degree of strategic uncertainty.
*   **Positives:**
    *   Recent uptrend indicated by moving averages and PPO.
    *   High and stable profit margins, increasing revenues, and improving ROE demonstrate financial strength.
    *   Analysts have a positive consensus rating.
    *   Recent news suggests that some institutions are buying the stock, and Morgan Stanley sees improvements.
    *  Medium risk indicator (MRI).

**Conclusion:**

While Merck shows some positive financial health indicators and a recent price uptrend, the significant underperformance compared to the S&P 500 and the negative expected return are major concerns. The analyst consensus provides some optimism, but the strategic uncertainty around the post-Keytruda era needs to be considered. The overbought RSI suggests caution in the short term.

The current Hybrid Signal recommends a cautious buying strategy, suggesting a small allocation to Merck, which aligns with the mixed signals from the data. This approach would allow for exposure to the company's potential upside while mitigating the risk of further underperformance.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.